Reaction

Product Dispensing Issue reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,531 reports · 54 co-occurring drugs

As of the last recalculation, Product Dispensing Issue appears in 3,531 FAERS reports alongside 54 co-occurring drug terms. The strongest observed disproportionality signal is BRIVARACETAM (PRR 29.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Brivaracetam	45	29.9	30.0
Insulin Glargine	792	24.1	24.2
Isotretinoin	154	19.1	19.2
Rotigotine	26	10.7	10.7
Lifitegrast	26	9.4	9.5
Icosapent Ethyl	10	6.9	6.9
Lacosamide	38	6.1	6.1
Certolizumab Pegol	116	6.0	6.0
Timolol Maleate	10	6.0	6.0
Travoprost	8	5.5	5.5
Oral Semaglutide	56	4.6	4.6
Dofetilide	8	4.5	4.5
Ropinirole	11	4.2	4.2
Emtricitabine And Tenofovir Alafenamide	8	4.2	4.2
Siponimod	6	4.0	4.0
Insulin Glargine-Yfgn	14	3.8	3.8
Brimonidine Tartrate	11	3.6	3.6
Prasugrel Hydrochloride	6	3.5	3.5
Levodopa	7	3.4	3.4
Budesonide, Glycopyrrolate, And Formoterol Fumarate	6	3.4	3.4
Pancrelipase	22	3.4	3.4
Carbidopa And Levodopa	26	3.2	3.2
Rasagiline Mesylate	6	3.2	3.2
Clobazam	13	3.1	3.1
Teduglutide	7	3.1	3.1
Mometasone Furoate And Formoterol Fumarate Dihydrate	8	3.0	3.0
Nirmatrelvir And Ritonavir	27	3.0	3.0
Somatropin	36	2.9	2.9
Linaclotide	13	2.9	2.9
Buprenorphine	41	2.6	2.6
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	8	2.6	2.6
Insulin Degludec	10	2.5	2.5
Bimekizumab	9	2.5	2.5
Fingolimod Hcl	36	2.5	2.5
Vigabatrin	6	2.4	2.4
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	4	2.3	2.3
Secukinumab	62	2.3	2.3
Suvorexant	5	2.3	2.3
Clozapine	47	2.2	2.2
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	15	2.1	2.1
Diclofenac Potassium, Film Coated	3	2.1	2.1
Diclofenac Potassium Tablets	3	2.1	2.1
Bosutinib	3	2.0	2.0
Ofatumumab	11	2.0	2.0
Palbociclib	30	1.9	1.9
Tirzepatide	47	1.7	1.7
Galcanezumab-Gnlm	8	1.5	1.5
Lenalidomide	104	1.5	1.5
Evolocumab	40	1.5	1.5
Pimavanserin Tartrate	13	1.4	1.4
Pomalidomide	19	1.1	1.1
Voxelotor	4	1.1	1.1
Esketamine Hydrochloride	3	1.0	1.0
Dupilumab	77	0.9	0.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.